Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Accenture
Medtronic
US Department of Justice
Cerilliant
Merck
Federal Trade Commission
McKesson
Harvard Business School
Mallinckrodt

Generated: October 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,034,908

« Back to Dashboard

Claims for Patent: 9,034,908

Title:Formulations of bendamustine
Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Inventor(s): Sundaram; Srikanth (Somerset, NJ)
Assignee: EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ)
Application Number:13/838,090
Patent Claims: 1. A method of treating cancer or malignant disease in a subject, comprising parenterally administering a volume of about 100 ml or less of a liquid composition comprising: a) from about 0.05 to about 12.5 mg/ml of bendamustine or a pharmaceutically acceptable salt thereof; b) a solubilizer comprising polyethylene glycol and propylene glycol, the polyethylene glycol being present in an amount of from about 0.3 to about 45% by volume and the propylene glycol being present in an amount of from about 0.03 to about 5% by volume; c) a parenterally acceptable diluent; and optionally d) an antioxidant; over a period of less than or equal to about 10 minutes to the subject.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt is from about 0.1 to about 6.0 mg/ml.

4. The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt is from about 0.05 to about 3.2 mg/ml.

5. The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt is from about 0.5 to about 5.6 mg/ml.

6. The method of claim 1, wherein the amount of solubilizer is from about 0.5 to about 26.5% vol.

7. The method of claim 1, wherein the amount of solubilizer is from about 0.2 to about 5% vol.

8. The method of claim 1, wherein the amount of solubilizer is from about 2.0 to about 22.4% vol.

9. The method of claim 1, where the polyethylene glycol is PEG 400.

10. The method of claim 1, wherein the weight ratio of polyethylene glycol to propylene glycol is about 90:10.

11. The method of claim 5, wherein the weight ratio of polyethylene glycol to propylene glycol is about 85:15.

12. The method of claim 1, wherein the volume administered is about 50, 30 or 15 ml.

13. The method of claim 1, wherein the antioxidant is monothioglycerol.

14. The method of claim 10, wherein the volume administered is about 50 ml or less.

15. The method of claim 1, wherein the cancer or malignant disease is chronic lymphocytic leukemia.

16. The method of claim 14, wherein the composition is administered intravenously in less than about 10 minutes on days 1 and 2 of a 28 day cycle.

17. The method of claim 14, wherein the composition is administered intravenously in less than about 10 minutes on days 1 and 2 of a 28 day cycle.

18. The method of claim 1, wherein the composition is administered for up to 6 cycles.

19. The method of claim 14, wherein the volume of the composition administered to the subject provides a bendamustine dosage amount ranging from about 25 mg/m.sup.2 to about 100 mg/m.sup.2 to the subject.

20. The method of claim 1, wherein the cancer or malignant disease is indolent B cell non-Hodgkin's lymphoma.

21. The method of claim 15, wherein the composition is administered intravenously in less than 10 minutes on days 1 and 2 of a 21 day cycle.

22. The method of claim 16, wherein the composition is administered for up to 8 cycles.

23. The method of claim 15, wherein the volume of the composition administered to the subject provides a bendamustine dosage amount ranging from about 60 mg/m.sup.2 to about 120 mg/m.sup.2 to the subject.

24. A method according to claim 1, wherein the bendamustine is present as the hydrochloride salt.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Queensland Health
Mallinckrodt
Deloitte
Baxter
Cantor Fitzgerald
Harvard Business School
Medtronic
Express Scripts
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot